Kornimate/medical-research-clean huggingface dataset:
targeted hip strength training in children with cerebral palsy (cp)

Conditions: Cerebral Palsy

Summary: this study's main aim is to look at targeted strength training for muscles at the hips. specifically to consider whether targeted strength training not only effects strength of the specific muscles but also ability to stand on one leg (single leg balance) as well as walking in children with cerebral palsy? this study is a feasibility of method of investigation.

this study is focusing on functional change. the reasoning is that if the targeted strength training is effective at improving hip muscle contribution to stability then single leg balance may be improved. this may be functionally evident when weight bearing is taken by say the left leg in gait (percentage stance phase of gait) and as a consequence the opposing swing phase will be optimised as measured by stride. thus the research question is does strengthening of the rotating and sideways moving hip muscles improve the walking of children with cp as measured by appropriate aspects of gait? secondly, does this targeted strengthening also increase duration of single leg balance which is a simple easy to use measure in the community without the need for specialised equipment? the primary outcome measure will use a laboratory based 4 camera codsmotion (coda) biomechanical analysis system to measure stride (a) and percentage duration of stance phase of gait (b). secondarily the duration of single leg balance in terms of seconds will be recorded. gross motor functional and quality of life as also being assessed. the intervention is strengthening which will be implemented with the principles of progressive resistance training. children with cp's therapists would ask for this type of intervention to be carried out

Eligibility criteria:
inclusion criteria: * children with cp aged between 7-16 years having sufficient cognition to undertake a strength training program exclusion criteria: 1. non-ambulation children or those unable to walk 5 meters independently (without walking aid), 2. lower limb surgery within 12 months, 3. botox within 6 months, 4. oral muscle relaxant medication 5. significant learning difficulty 6. any concurrent condition which would be contraindicated to progressive resistance training such as unmanaged high blood pressure, cardiac pathology or uncontrolled epilepsy 7. where at baseline assessment finds no weakness in the muscles under investigation 8. concurrent or within 6 months involvement in any other research study 9. non consent to general practitioner (gp) notification.

Keywords: single blinded randomised controlled physiotherapy children cerebral palsy
pain control and subconjunctival hemorrhage size after intravitreal injection

Conditions: Intravitreal Injection; Pain; Subconjunctival Hemorrhage

Summary: intravitreal injections (ivi) are the mainstay of treatment modality in many ophthalmologic diseases including neovascular age-related macular degeneration (amd), diabetic retinopathy and retinal vascular occlusions. patients endure monthly ivi for several years. although standardized topical anesthesia protocols are being carried out, many still suffer from pain during and after the procedure. previous studies at the investigators clinic have demonstrated that alpha-agonist eye drops and cool eye compresses can be successfully used in order to reduce pain levels when administered prior to ivi. in the current research, the investigators wish to study whether cooled anesthetic eye drops and antiseptics can be utilized as well to reduce the pain and subconjunctival hemorrhage caused by bevacizumab ivi.


Eligibility criteria:
inclusion criteria: * participants over the age of 18 years, receiving bevacizumab ivi who are capable of signing a written informed consent form obtained under the declaration of helsinki. exclusion criteria: * no consent to participate in the study. * incapability of signing a written informed consent form.

Keywords: intravitreal injection pain subconjunctival hemorrhage bevacizumab eye drops
testing a smart phone app to enhance voice therapy adherence

Conditions: Voice Disorders

Summary: the current project is designed as phase 1 study conducted to improve/enhance normal voice. fifteen thirty non-treatment seeking individuals, with no identifiable vocal pathology on laryngeal examination, will be randomized to one of two groups; 1) voice therapy delivery without app (control/standard of care), 2) voice therapy delivery with app (experimental). participants in both groups will attend weekly voice therapy sessions (for 6 weeks) with the pi and co- i (joseph stemple). control group participants will be provided with an audio file of the exercises, and an exercise log sheet to track progress. experimental group participants will use the smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track. three-wave surveys will be conducted at the baseline, four weeks and 6 weeks after the intervention. other data sources include study administration, exercise logs, app data, and clinical assessment.


Eligibility criteria:
inclusion criteria: 1. adults \> 18 years 2. non-smokers 3. hearing level within normal limits 4. absence of vocal fold pathology as confirmed by md on laryngeal examination 5. agree to avoid vocally abusive behaviors for the entirety of the study exclusion criteria: 1. apple phone (ios) 2. impaired hearing 3. uncontrolled asthma 4. smoking 5. h/o vocal fold surgery 6. presence of vocal fold pathology 7. previous history of experience with vfe performance 8. non-english speaking participants

Keywords: adherence
avastin (bevacizumab) in the treatment of metastatic colorectal cancer in normal clinical use in the uk population

Conditions: Metastatic Colorectal Cancer

Summary: this study will focus on participants in the united kingdom (uk) to collect local data on the effectiveness and safety of bevacizumab (avastin) in the treatment of metastatic colorectal cancer in normal clinical use.


Eligibility criteria:
inclusion criteria: * have been diagnosed with metastatic colorectal cancer (mcrc) * have a performance status (ps) of 0-2, according to the eastern cooperative oncology group (ecog) criteria at initiation of bevacizumab treatment * be chemotherapy-naive at diagnosis of mcrc or have relapsed more than 12 months after receiving adjuvant chemotherapy for early stage colorectal cancer * have received standard fluoropyrimidine-based chemotherapy for first-line treatment of mcrc with or without bevacizumab * have sufficient medical records available for assessment of eligibility at the christie hospital national health service (nhs) trust, manchester, united kingdom * for cohort 1 (post cdf funding availability): patients between 2010-2013 who received bevacizumab with first-line chemotherapy * for cohort 2 (pre cancer drugs fund \[cdf\] funding availability): patients propensity matched to cohort 1 between 2005-2008 who did not receive bevacizumab with first-line chemotherapy exclusion criteria: * subjects with metastatic colorectal cancer, who have received bevacizumab via a clinical trial * subjects with metastatic colorectal cancer, whose medical records are not complete enough to confirm eligibility for the study
safety and efficacy of punctal plug insertion in patients with dry eye

Conditions: Dry Eye

Summary: this study will access changes in tear protein levels and symptoms of dry eye following insertion of a punctal plug.


Eligibility criteria:
inclusion criteria: * patients with moderate to severe dry eye exclusion criteria: * previous punctal plug insertion in the last 3 months or presence of plugs at the time of study * contact lens wear in the 7 days prior to study start or during the study * lasik procedure in the last year * cataract or other eye surgery in the last 3 months * corneal grafts
efficacy of short-term immunosuppressive therapy and anti-allergenic therapy in severe acute exacerbation of chronic hepatitis b

Conditions: Severe Acute Exacerbation of Chronic Hepatitis B

Summary: the investigators will investigate the clinicopathological features of chronic hepatitis b patients with severe exacerbation selected by uniform criteria, and treated with early introduction or reintroduction of corticosteroids and anti-allergenic therapy, in order to clarify the benefits and limitations of the effects of corticosteroids and anti-allergenic therapy for amelioration of clinically severe exacerbation of chronic hepatitis b. the investigators also observe the immune index in the change before and after the treatment, in order to searching for some prognostic index.


Eligibility criteria:
inclusion criteria: * serum hepatitis b surface antigen(hbsag) positive for at least 6 months; * all patients had a poor general condition, manifested as general malaise, fatigue, jaundice and so on; * serum t-bil of 85.5 mmol/l or more; or serum t-bil rises 17.1 mmol/l or more per day; or pta of less than 60%; * serum alt of 20 times or more the uln. exclusion criteria: * superinfection or co-infection with hepatitis a, c, d, e, cytomegalovirus and hiv, or epstein-barr virus; * other liver diseases such as alcoholic liver disease, drug-induced hepatitis, wilson disease and autoimmune hepatitis; * ascites or gastrointestinal bleeding or peptic ulcer or esophageal varix by electronic gastroscope examination; * decompensated liver cirrhosis; * severe bacterial or fungal infections; * a history of diabetes or cardiac disease or hypertension or nephrosis.
stereotactic salvage radiotherapy for macroscopic prostate bed recurrence after prostatectomy-a prospective observational study

Conditions: Prostate Cancer; Relapse

Summary: stereotactic salvage radiotherapy for macroscopic prostate bed recurrence after prostatectomy (starr trial) is a prospective observational study aimed to assess outcome after stereotactic salvage radiotherapy (ssrt) for macroscopic prostate bed recurrence after radical prostatectomy.

this is a prospective observational multicenter study including patients affected by patients with macroscopic recurrence within prostate bed after rp detected with choline or psma ct-pet and confirmed with pelvic mri (except for cases in which mri is contraindicated). patients will be treated with ssrt on macroscopic prostate bed recurrence for a total dose of from 35 in 5 fractions. planned size of the overall study population is 90 patients. the study will include a screening phase and a treatment phase. the screening phase allows for assessment of subject eligibility, demographics, psa, comorbidities and current drug therapies up to 45 days prior to randomization. the treatment phase consists of ssrt administered on prostate bed macroscopic recurrence. different techniques will be allowed provided that treatment respects doses and fractionation indicated per-protocol (35 gy in 5 fractions) and that dose constraints to organs at risk (oar) reported in this document are observed. the total planned duration of the study is 40 months, consisting in 16 months enrollment period, during which patients will perform the screening and and later phase of 24 months in which patients will continue to be submitted to periodic checks every 3 months.

Eligibility criteria:
inclusion criteria: * patients affected by biochemical recurrence after radical prostatectomy for prostate cancer (defined as a psa increase \> 0.2 ng/ml) * presence of macroscopic recurrence in prostate bed, determined with either choline or psma pet imaging and confirmed through mri (except for cases in which mri is contraindicated) * absence of distant and/or regional sites of disease outside prostate bed * patients free from androgen deprivation therapy (adt) (adjuvant adt after radical prostatectomy for pn+ patients is allowed if \> 12 months from biochemical recurrence) exclusion criteria: * presence of distant and/or regional sites of disease outside prostate bed * patient undergoing adt or withdrawal of adjuvant adt within12 months from biochemical recurrence * absence of disease detection from one of the two imaging modalities used (choline or psma pet and mri must be positive- except for cases in which mri is contraindicated) * any condition for which, in the opinion of the treating physician, ssrt would be contraindicated for the patient (i.e peristence of moderate/severe urinary distress after prostatectomy, post-surgical complications etc)
the impact of mechanical methods on the postpartum haemorrhage prophylaxis during caesarean section

Conditions: Postpartum Hemorrhage; Cesarean Section Complications

Summary: the rate of heavy blood loss is higher in cesarean delivery compared to vaginal deliveries. since postpartum hemorrhage is a life threatening situation to decrease the maternal mortality and morbidity rates, precautions should be taken. in this study, we aim to decrease the amount of postpartum hemorrhage by clamping the uterine artery after the delivery of the baby during cesarean delivery.

obstetrical hemorrhage, is the most common cause of maternal mortality and morbidity that could be prevented. it can appear at early and late stage of delivery and after delivery. it is defined as loss of more than 500 ml of blood in vaginal deliveries, whereas more than 1l of blood during c-section. the rate of heavy blood loss is higher in cesarean delivery compared to vaginal deliveries. the incidence of postpartum anemia in europe is 50% while in developing countries like turkey it rises up to 50-80%. since postpartum hemorrhage is a life threatening situation to decrease the maternal mortality and morbidity rates, precautions should be taken. to preserve the hemoglobin concentrations and hemostasis and to optimize the patient's results, evidence-based methods should be performed. given these circumstances, interventions using pharmacological, mechanical and surgical methods are necessary to minimize the blood loss. uteroronics are the first line treatment options followed by fundal massage, controlled traction of cord and delivery of placenta, bimanual compression, intrauterine hydrostatic balloon. after these interventions, surgical interventions such as compression sutures, bilateral uterine artery ligation, hysterectomy and pelvic tamponade could be performed. in this study, we aim to decrease the amount of preoperative part of postpartum hemorrhage by clamping the uterine artery by darmklemmen clamp after the delivery of the baby before the delivery of placenta during cesarean delivery.

Eligibility criteria:
inclusion criteria: * women gave birth \>37 gw * singleton pregnancy * with normal fetal development * not emergency c-section exclusion criteria: * c/sections with indications of plasenta prevue or placenta acrreta spectrum * with amniotic fluid abnormalities * multiple pregnancies * threatened preterm labor * who have preeclampsia or other type of obstetrical complications * maternal obesity (bmi\>30kg/m2) * maternal cardiovascular disease, hypertension, coagulation defects, women who use anticoagulants * patients who underwent cesarean section during active labor

Keywords: postpartum hemorrhage cesarean section
transcriptomics and epigenetics analysis in drug-resistance of multiple myeloma

Conditions: Multiple Myeloma

Summary: multiple myeloma (mm) is the more common hematological neoplastic disease second only to hodgkin lymphoma. in mm patients, mutated genes are mainly kras (23%), nras (20%), fam46c (11%), dis3 (11%) e tp53 (8%). epigenetics studies suggested that changes in histone modifications and dna methylation pattern, as well as non-coding rnas (mirnas) expression are involved in mm development. in particular, it has been shown that the aberrant expression of different mirnas could discriminate healthy from ill patients. unfortunately, the main critical issue for an effective treatment of mm is the intrinsic or acquired resistance to pharmacological treatments, due also to a plasmacellular clonal heterogeneity. the prospective study will involve a patient cohort with mgus, mm smouldering and mm, with the aim to characterize different transcriptional and epigenetic features, also including mirnas, among mm cells susceptible or resistant to conventional therapies. the final goal is to identify new prognostic and predictive biomarkers that could be used as therapeutic tools to improve clinical targeted therapies.


Eligibility criteria:
inclusion criteria: - compare transcriptomics and epigenetic profile exclusion criteria: * no exclusion criteria
perioperative monitoring of cardiac surgery patients with the vitalstream physiological monitor

Conditions: Cardiac Output, Low; Stroke Volume

Summary: the purpose of this study is to validate cardiac output and stroke volume derived from vitalstream against gold standard measurements obtained using thermodilution. the vitalstream device is a continuous noninvasive physiological monitor (caretaker medical llc, charlottesville, virginia, further referred to as "ctm") provides heart rate, continuous noninvasive blood pressure (bp), respiratory rate, stroke volume and cardiac output.

the device is currently undergoing iec 60601 medical safety standards testing and has already passed all fda-required emission and discharge testing. the vitalstream tracks central aortic bp via pulse analysis, specifically pulse decomposition analysis ("pda"), of the peripheral pulse at a distal site, typically finger. the device uses a low pressure \[30-40 mmhg\], pump-inflated, finger cuff that pneumatically couples arterial pulsations via a pressure line to a custom-designed piezo-electric pressure sensor for detection and analysis. physiological data are communicated wirelessly to a tablet-based user interface via bluetooth. the vitalstream monitor is most beneficial as it is non-invasive, is a minimal risk device, and for this protocol will not be utilized to make treatment decisions for the study subject.

Eligibility criteria:
inclusion criteria: * adult post-cardiac surgery needing cardiopulmonary bypass and use of the pulmonary artery catheter (pac) as standard of care, (s/p coronary artery bypass graft (cabg), valve, heart transplant, major aortic \& other vascular surgery, and a combination of cabg and valve procedures) * patients (age \> 18) admitted to the intensive care unit (icu) with a pulmonary artery catheter (continuous or intermittent thermodilution cardiac output) and an arterial catheter for blood pressure (bp) monitoring (standard of care) exclusion criteria: * patients without an appropriately positioned or functioning (pac) pulmonary artery catheter admitted to the cardiac surgery icu after surgery. patients on left ventricular assist device (lvad) support

Keywords: cardiac output cardiac surgery pulmonary artery catheter
direct anterior approach versus direct lateral approach in total hip arthroplasty

Conditions: Coxarthrosis

Summary: the purpose of this study is to compare the direct anterior approach and the direct lateral approach in primary total hip arthroplasty, regarding the postoperative function and pain, complications, radiological finds (x-ray), postoperative hemorrhage, markers for muscle damage (i.e creatine kinase (ck), lactate dehydrogenase(ldh/ld) , aspartate aminotransferase(ast), c-reactive protein (crp),troponin and myoglobin) or other clinical outcomes.

this is a prospective randomised controlled clinical trial and follow-up study comparing primary total hip arthroplasty performed either through a direct anterior approach or a lateral approach. at our hospital(i.e. emergency county hospital cluj-napoca), the lateral transgluteal approach was standard for more than 40 years. starting 2008,the minimally invasive anterior approach was gradually implemented with the aim to facilitate early rehabilitation and improve functional results. reduced blood loss, earlier functional recovery, low dislocation rates and shorter stays in hospital have been attributed to the muscle-sparing properties of the anterior approach.

Eligibility criteria:
inclusion criteria: * clinical and radiological diagnosis of coxarthrosis * those deemed capable of giving informed consent, understanding the aims of the study and expressing willingness to comply with the post-operative review programme. exclusion criteria: * previous surgery on affected hip * the patient has inflammatory arthritis. * the patient has any type of infection. * the subject has a known metal allergy. * patients with co-existent ipsilateral knee disease or back problems * those with a known co-existent medical condition where death is anticipated within five years due to the pre-existing medical condition. * patients requiring bilateral hip replacement. * patient with active major psychiatric illness * patients whose body mass index (bmi; kg/m2) \>35. * patients with active or suspected infection or sepsis. * patients with renal failure and/or renal insufficiency.

Keywords: coxarthrosis hip arthroplasty direct anterior approach direct lateral approach
a study of xeloda (capecitabine) in women with her2-negative metastatic breast cancer

Conditions: Breast Cancer

Summary: this single-arm study was designed to evaluate the efficacy and safety of oral xeloda plus intravenous avastin as first-line treatment in women with metastatic breast cancer. patients received xeloda 1000 mg/m² orally (po) twice daily (bid) on days 1-15, and avastin 15 mg intravenously (iv) on day 1 of each 3-week cycle. the anticipated time on study treatment was until disease progression or unacceptable toxicity. the target sample size was \<100 individuals.


Eligibility criteria:
inclusion criteria: * women \>=18 years of age * her2-negative metastatic breast cancer * previous adjuvant chemotherapy or hormonal treatment * \>=1 measurable target lesion exclusion criteria: * previous treatment with chemotherapy, an anti-angiogenic agent, or a biologic therapy for advanced or metastatic cancer * radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy * central nervous system metastases * other malignancy within last 5 years, except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix * serious concurrent infection